- Investment round led by Novo Holdings A/S (“Novo Holdings”), joined by a syndicate of international biotech investors
- Hummingbird to advance lead assets in clinical trials and build next-generation portfolio of precision therapeutics for elusive targets in oncology and autoimmune diseases
- Kenneth Harrison, Partner, Novo Ventures (US), Inc. (“Novo Ventures”), to join Hummingbird board
Copenhagen, Denmark, 18 May 2021 – Novo Holdings today announced that it has led the oversubscribed US$125 million Series C financing in Hummingbird Bioscience (Hummingbird), an innovative clinical-stage biotech company focused on developing precision therapies against difficult-to-drug targets to improve treatment outcomes. This is one of the first investments in a privately-held Asian biotech company by Novo Holdings. Novo Holdings recently established an Asian life sciences investment platform in Singapore, Novo Holdings Equity Asia Pte. Ltd. (“Novo Holdings Asia”). Kenneth Harrison, Partner, Novo Ventures, will join Hummingbird’s board of directors.